OBJECTIVE: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. PATIENTS AND METHODS: We studied 16 patients (median age, 64 years) who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. RESULTS: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56%) and IIIB in 7 (44%). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25%) prior stem cell transplantation had failed, and 14 (88%) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25%) achieved a partial response to therapy, with a greater than 50% reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. CONCLUSION: Thalidomide is an active agent in the treatment of patients with advanced myeloma.
OBJECTIVE: To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma. PATIENTS AND METHODS: We studied 16 patients (median age, 64 years) who received thalidomide for relapsed myeloma at the Mayo Clinic in Rochester, Minn, between November 1998 and August 1999. Treatment consisted of thalidomide given orally at a dose of 200 mg/d for 2 weeks, then increased by 200 mg/d every 2 weeks, up to a maximal dose of 800 mg/d. RESULTS: The stage of myeloma at treatment was Durie-Salmon IIIA in 9 patients (56%) and IIIB in 7 (44%). The median time from myeloma diagnosis to initiation of thalidomide therapy was 32 months. In 4 patients (25%) prior stem cell transplantation had failed, and 14 (88%) had received 2 or more prior chemotherapeutic regimens before institution of thalidomide. All patients were evaluable for response. Four (25%) achieved a partial response to therapy, with a greater than 50% reduction in the serum or urine M protein level. Responses lasted 2, 4+, 8, and 10+ months. Major adverse effects included constipation, sedation, rash, and peripheral neuropathy. CONCLUSION:Thalidomide is an active agent in the treatment of patients with advanced myeloma.
Authors: Clemens C Cyran; Barbara Sennino; Bundit Chaopathomkul; Yanjun Fu; Victor S Rogut; David M Shames; Michael F Wendland; Donald M McDonald; Robert C Brasch Journal: Eur Radiol Date: 2008-07-30 Impact factor: 5.315
Authors: Neil Majithia; S Vincent Rajkumar; Martha Q Lacy; Francis K Buadi; Angela Dispenzieri; Morie A Gertz; Suzanne R Hayman; David Dingli; Prashant Kapoor; Lisa Hwa; John A Lust; Stephen J Russell; Ronald S Go; Robert A Kyle; Shaji K Kumar Journal: Am J Hematol Date: 2015-10-06 Impact factor: 10.047
Authors: Aldo M Roccaro; Irene M Ghobrial; Simona Blotta; Steven P Treon; Michele Malagola; Kenneth C Anderson; Paul G Richardson; Domenico Russo Journal: Biologics Date: 2008-09
Authors: Christine Chen; Donna E Reece; David Siegel; Ruben Niesvizky; Ralph V Boccia; Edward A Stadtmauer; Rafat Abonour; Paul Richardson; Jeffrey Matous; Shaji Kumar; Nizar J Bahlis; Melissa Alsina; Robert Vescio; Steven E Coutre; Dennis Pietronigro; Robert D Knight; Jerome B Zeldis; Vincent Rajkumar Journal: Br J Haematol Date: 2009-05-26 Impact factor: 6.998